Research in practice: Treatment of autoimmune bullous disorders;Forschen für die Praxis: Therapie bullöser Autoimmunerkrankungen

JDDG - Journal of the German Society of Dermatology

Volumn 7, Issue 6, 2009, Pages 500-505

  Hertl, Michael ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Autoantibody; Blister formation; Immune pathogenesis; Immunosuppression; Serological diagnostics; T cells

Indexed keywords

AUTOANTIGEN; COLLAGEN TYPE 17; HLA ANTIGEN CLASS 2; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; KALININ; RITUXIMAB;

AUTOIMMUNE SKIN DISEASE; B LYMPHOCYTE; BULLOUS SKIN DISEASE; CLONAL ANERGY; DISEASE COURSE; DRUG MEGADOSE; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; IMMUNOADSORPTION; IMMUNOPATHOGENESIS; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; MOLECULAR MECHANICS; PEMPHIGOID; PEMPHIGUS; REVIEW; SEROLOGY; T LYMPHOCYTE; TH2 CELL;

AUTOIMMUNE DISEASES; DERMATOLOGIC AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; SKIN DISEASES, VESICULOBULLOUS;

EID: 67449116511     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2009.07023.x     Document Type: Review

References (26)

1. Hertl M, Eming R, Veldman C. T cell control in autoimmune bullous skin disorders. J Clin Invest. 2006 116 : 1159 566.
2. Hertl M, Amagai M, Sundaram H, Stanley J, Ishii K, Katz SI. Recognition of desmoglein 3 by autoreactive T cells in pemphigus vulgaris patients and normals. J Invest Dermatol. 1998 110 : 62 6. (Pubitemid 28086065)
3. Hertl M, Karr RW, Amagai M, Katz SI. Heterogeneous MHC II restriction pattern of autoreactive desmoglein 3 specific T cell responses in pemphigus vulgaris patients and normals. J Invest Dermatol. 1998 110 : 388 92. (Pubitemid 28158655)
4. Büdinger L, Borradori L, Yee C, Eming R, Ferencik S, Grosse-Wilde H, Merk HF, Yancey K, Hertl M. Identification and characterization of autoreactive T cell responses to bullous pemphigoid antigen 2 in patients and healthy controls. J Clin Invest. 1998 102 : 2082 9. (Pubitemid 29018814)
5. Veldman C, Stauber A, Wassmuth R, Uter W, Schuler G, Hertl M. Dichotomy of autoreactive Th1 and Th2 cell responses to desmoglein 3 in patients with pemphigus vulgaris (PV) and healthy carriers of PV-associated HLA class II alleles. J Immunol. 2003 170 : 635 42. (Pubitemid 36026193)
6. Gebhard KL, Veldman CM, Wassmuth R, Schultz E, Schuler G, Hertl M. Ex vivo analysis of desmoglein 1-responsive T-helper (Th) 1 and Th2 cells in patients with pemphigus foliaceus and healthy individuals. Exp Dermatol. 2005 14 : 586 92. (Pubitemid 41030925)
7. Eming R, Büdinger L, Riechers R, Christensen O, Bohlen H, Kalish R, Hertl M. Frequency analysis of autoreactive T-helper 1 and 2 cells in bullous pemphigoid and pemphigus vulgaris by enzyme-linked immunospot assay. Br J Dermatol. 2000 143 : 1279 82. (Pubitemid 32052768)
8. Veldman CM, Gebhard KL, Uter W, Wassmuth R, Grötzinger J, Schultz E, Hertl M. T cell recognition of desmog-lein 3 peptides in patients with pemphigus vulgaris and healthy individuals. J Immunol. 2004 172 : 3883 92. (Pubitemid 38337976)
9. Thoma-Uszynski S, Uter W, Schwietzke S, Schuler G, Borradori L, Hertl M. Autoreactive T and B cells from bullous pemphigoid (BP) patients recognize epitopes clustered in distinct regions of BP180 and BP230. J Immunol. 2006 176 : 2015 23. (Pubitemid 43134347)
10. Haase C, Büdinger L, Borradori L, Yee C, Merk HF, Yancey K, Hertl M. Detection of IgG autoantibodies in the sera of patients with bullous and gestational pemphigoid: ELISA studies utilizing a baculovirus-encoded form of bullous pemphigoid antigen 2. J Invest Dermatol. 1998 110 : 282 6. (Pubitemid 28144606)
11. Hofmann S, Thoma-Uszynski S, Hunziker T, Bernard P, Koebnick C, Stauber A, Schuler G, Borradori L, Hertl M. Severity and phenotype of bullous pemphigoid relate to autoantibody profile against the NH2- and COOH-terminal regions of the BP180 ectodomain. J Invest Dermatol. 2002 119 : 1065 73. (Pubitemid 35430484)
12. Thoma-Uszynski S, Uter W, Schwietzke S, Hofmann SC, Hunziker T, Bernard P, Treudler R, Zouboulis CC, Schuler G, Borradori L, Hertl M. BP230- and BP180-specific auto-antibodies in bullous pemphigoid. J Invest Dermatol. 2004 122 : 1413 22. (Pubitemid 38757223)
13. Eming R, Schmidt J, Schwietzke S, Podstawa E, Müller R, Sonderstrup G, Hertl M. HLA class II-restricted autoaggressive T cells shape the auto-antibody response against desmoglein 3 (dsg3) in an HLA-transgenic mouse model of pemphigus vulgaris (PV). Exp. Dermatol. 2007 16 : 218A.
14. Veldman C, Höhne A, Dieckmann D, Schuler G, Hertl M. Type I regulatory T cells specific for desmoglein 3 are more frequently detected in healthy individuals than in patients with pemphigus vulgaris. J Immunol. 2004 172 : 6468 75. (Pubitemid 38621257)
15. Veldman C, Pahl A, Beissert S, Hansen W, Buer J, Dieckmann D, Schuler G, Hertl M. Inhibition of the transcription factor Foxp3 converts desmoglein 3-specific type 1 regulatory T cells into Th2-like cells. J Immunol. 2006 176 : 3215 22. (Pubitemid 43306985)
16. Joly P, Mouquet H, Roujeau JC, D'Incan M, Gilbert D, Jacquot S, Gou-geon ML, Bedane C, Muller R, Dreno B, Doutre MS, Delaporte E, Pauwels C, Franck N, Caux F, Picard C, Tancrede-Bohin E, Bernard P, Tron F, Hertl M, Musette P. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med. 2007 357 : 545 52. (Pubitemid 47236279)
17. Eming R, Nagel A, Wolff-Franke S, Podstawa E, Debus D, Hertl M. Rituximab exerts a dual effect in pemphigus vulgaris. J Invest Dermatol. 2008 128 : 2850 8.
18. Nagel A, Hertl M, Eming R. B cell directed therapy of inflammatory skin diseases. J. Invest. Dermatol im Druck).
19. Eming R, Rech J, Barth S, Kalden JR, Schuler G, Harrer T, Hertl M. Prolonged clinical remission of patients with severe pemphigus upon rapid removal of desmoglein-reactive autoantibodies by immunoadsorption. Dermatology 2006 212 : 177 87. (Pubitemid 43260734)
20. Enk A, Hertl M, Messer G, Meurer M, Rentz E, Zillikens D. The use of high dose intravenous immunoglobulins in dermatology. J Dtsch Dermatol Ges. 2003 1 : 183 90. (Pubitemid 36565285)
21. Mayrshofer F, Hertl M, Sinkgraven R, Sticherling M, Pfeiffer C, Zillikens D, Messer G, Rzany für die Deutsche BSD-Studiengruppe B. Significant decrease in quality of life in patients with pemphigus vulgaris. Results from the German Bullous Skin Disease (BSD) Study Group. J Dtsch Dermatol Ges. 2005 3 : 431 5. (Pubitemid 40825106)
22. Pfütze M, Niedermeier A, Hertl M, Eming R. Introducing a novel autoimmune bullous skin disorder intensity score (ABSIS) in pemphigus. Eur J Dermatol. 2007 17 : 4 11. (Pubitemid 46383213)
23. Di Zenzo G, Thoma-Uszynski S, Fontao L, Calabresi V, Hofmann SC, Hellmark T, Sebbag N, Pedicelli C, Sera F, Lacour JP, Wieslander J, Bruckner-Tuderman L, Borradori L, Zambruno G, Hertl M. Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid. Clin Immunol. 2008 128 : 415 26.
24. Veldman C, Eming R, Wolff-Franke S, Sonderstrup G, Kwok WW, Hertl M. Detection of low avidity desmoglein 3-reactive T cells in pemphigus vulgaris using HLA-DR beta 1*0402 tetramers. Clin Immunol. 2007 122 : 330 7. (Pubitemid 46223650)
25. Müller R, Svoboda V, Wenzel E, Gebert S, Hunzelmann N, Müller HH, Hertl M. IgG reactivity against non-conformational NH-terminal epitopes of the desmoglein 3 ectodomain relates to clinical activity and phenotype of pemphigus vulgaris. Exp Dermatol. 2006 15 : 606 14. (Pubitemid 43983848)
26. Müller R, Svoboda V, Wenzel E, Müller HH, Hertl M. IgG against extracellular subdomains of desmoglein 3 relates to clinical phenotype of pemphigus vulgaris. Exp Dermatol. 2008 17 : 35 43. (Pubitemid 350269210)